Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 3/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3662356 | 0.84 | APP (0.34) | MAOBAPPMAOACYP1A2 | |
| SCHEMBL3660251 | 0.83 | EGFR (0.34) | MAOBTSHRHTR1AAPPMAOA | |
| SCHEMBL3662868 | 0.83 | APP (0.35) | HTR1AAPP | |
| Hydrochloric Acid SCHEMBL3663052 | 0.82 | EGFR (0.34) | MAOBTSHRHTR1AAPPMAOA | |
| SCHEMBL3662259 | 0.82 | L3MBTL1 (0.36) | CYP3A4MAOBTSHRHTR1AAPP | |
| SCHEMBL3656186 | 0.81 | APP (0.34) | APPCYP1A2 | |
| SCHEMBL3659751 | 0.81 | EGFR (0.35) | CYP3A4MAOBTSHRHTR1AAPP | |
| SCHEMBL3664516 | 0.81 | EGFR (0.35) | CYP3A4MAOBTSHRHTR1AAPP | |
| SCHEMBL3656907 | 0.79 | PTGS2 (0.34) | HTR1AAPP | |
| SCHEMBL30060702 | 0.78 | CYP3A4 (0.44) | MAPTCYP3A4CYP2A6MAOBHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311790-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | SUMITOMO CHIEMCAL COMPANY LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2215062-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | Sumitomo Chemical Company, Limited (JP) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009069792-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311790-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | ATL3, NAT1, C5 | MAPT 947/4885CYP3A4 3941/4885CYP2A6 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.